{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"20","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of three consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l. The CBCs obtained should be at least seven days after the most recent platelet transfusion. Only patients who achieved engraftment of platelets will be included in the analysis. The median and 95% confidence intervals will be provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase II"}],"paramType":"MEDIAN","populationDescription":"All patients who received treatment and who achieved platelet recovery/engraftment of platelets","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) through 1 year post-transplant","title":"Phase II - Time to Platelet Engraftment","type":"SECONDARY","unitOfMeasure":"days"}